戻る Agenda
Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies
Session Chair(s)
William Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer Inc, United States
Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies
Speaker(s)
Speaker
Peter F. Bross, MD
FDA, United States
Medical Review Officer OTAT, CBER
Speaker
William Gregory, PhD
Pfizer Inc, United States
Senior Director, Safety and Risk Management